Kyverna Therapeutics, Inc. (KYTX) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$39.12M*; Operating income -$39.56M; Depreciation and amortization $434.00K*.
- 2026-03-31: Basis Reported; EBITDA -$41.02M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$38.91M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$38.31M*; Operating income -$38.73M; Depreciation and amortization $415.00K*.
Complete source-backed ebitda history.
- Available history
- 2023-03-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$39.12M* | -$39.56M | $434.00K* | (m) | (m) | (m) | -$40.31M* | (m) | $24.79M | (m) | (m) |
|---|
| 2026-03-31 | Reported | -$41.02M | (m) | (m) | (m) | (m) | (m) | -$41.60M | (m) | $30.07M | (m) | (m) |
|---|
| 2025-12-31 | Reported | -$38.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$38.31M* | -$38.73M | $415.00K* | (m) | (m) | $2.00K* | -$43.32M* | (m) | $30.46M | (m) | (m) |
|---|
| 2025-06-30 | Reported | -$43.90M* | -$44.41M | $515.00K* | (m) | (m) | $4.00K* | -$31.95M* | (m) | $35.82M | (m) | (m) |
|---|
| 2025-03-31 | Reported | -$46.91M | (m) | (m) | (m) | (m) | $0.00 | -$44.91M | (m) | $37.43M | (m) | (m) |
|---|
| 2024-12-31 | Reported | -$40.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$38.21M* | -$38.77M | $558.00K* | (m) | (m) | $102.00K* | -$27.49M* | (m) | $29.19M | (m) | (m) |
|---|
| 2024-06-30 | Reported | -$32.91M* | -$33.44M | $530.00K* | (m) | (m) | $1.03M* | -$24.18M* | (m) | $27.32M | (m) | (m) |
|---|
| 2024-03-31 | Reported | -$28.88M | (m) | (m) | (m) | (m) | $543.00K | -$25.52M | (m) | $22.48M | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$20.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$15.84M* | -$16.28M | $438.00K* | (m) | (m) | $256.00K* | -$11.13M* | (m) | $13.64M | (m) | (m) |
|---|
| 2023-06-30 | Reported | -$12.89M* | -$13.30M | $413.00K* | (m) | (m) | $3.00K* | -$11.26M* | (m) | $10.40M | (m) | (m) |
|---|
| 2023-03-31 | Reported | -$11.05M | (m) | (m) | (m) | (m) | $28.00K | -$11.46M | (m) | $8.71M | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$168.03M | (m) | (m) | (m) | (m) | $5.00K | -$153.71M | (m) | $133.72M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$140.47M | (m) | (m) | (m) | (m) | $2.21M | -$114.25M | (m) | $112.47M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$60.7M | (m) | (m) | (m) | (m) | $621.00K | -$52.41M | (m) | $49.92M | (m) | $0.00 |
|---|